Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation

被引:116
作者
Roldán, V
Marín, F
Blann, AD
García, A
Marco, P
Sogorb, F
Lip, GYH [1 ]
机构
[1] City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
[2] Hosp San Vicente, Hematol Unit, Alicante, Spain
[3] Gen Hosp, Dept Cardiol, Alicante, Spain
[4] Gen Hosp, Dept Haematol, Alicante, Spain
关键词
atrial fibrillation; hypercoagulable; inflammation;
D O I
10.1016/S0195-668X(03)00239-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background A prothrombotic or hypercoagulable state has been described in AF, which could increase the risk of thromboembolism. As inflammation has been related to thrombogenesis and endothetial activation, we hypothesised that the prothrombotic state in AF (as assessed by an index of thrombogenesis, prothrombin fragment 1+2 [F1+2]) and endothelial activation (soluble E-selectin (sEsel)) could be related to an index of inflammation (interleukin-6 (IL-6)). Patients and methods We studied 191 consecutive patients (98 mate; mean age 72.3 +/- 9.2years) with chronic non-rheumatic AF who were not on anticoagulant therapy. Plasma IL-6, sEset and F1+2 were measured by ELISA. Research indices were compared to 74 controls in sinus rhythm matched for age and sex. In 43 patients with AF, the effects of introducing anticoagulation (INR 2.0-3.0) were also studied. Results Patients with AF had elevated levels of F1 +2 (p<0.001) and IL-6 (p=0.045), but not sEsel. There was no significant correlation between F1 +2 and IL-6. In multivariate analysis, only F1+2 levels were independently associated with the presence of AF (p=0.001). After oral anticoagulation, plasma levels of F1+2 and sEsel were significantly decreased (both p<0.01). Conclusion High levels of IL-6 in AF suggest an inflammatory state, which appears to be more related to clinical variables of the patients, rather than to the presence of AF per se. There was no association of inflammation with endothelial activation (sEset) or the presence of abnormal thrombogenesis (high F1+2 levels) in AF. Moreover, no changes in IL-6 levels were found despite the reduction of the other markers by oral anticoagulant therapy. (C) 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
引用
收藏
页码:1373 / 1380
页数:8
相关论文
共 50 条
  • [1] Neopterin and interleukin-6 as predictors of recurrent atrial fibrillation
    Lewicka, Ewa
    Dudzinska-Gehrmann, Julita
    Dabrowska-Kugacka, Alicja
    Zagozdzon, Pawel
    Lizewska, Aleksandra
    Danilowicz-Szymanowicz, Ludmila
    Raczak, Grzegorz
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2016, 16 (08) : 563 - 571
  • [2] Interleukin-6: Molecular Mechanisms and Therapeutic Perspectives in Atrial Fibrillation
    Yu, Jin-fang
    Dong, Qian
    Du, Yi-mei
    CURRENT MEDICAL SCIENCE, 2025, : 157 - 168
  • [3] The-174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication?
    Gaudino, M
    Andreotti, F
    Zamparelli, R
    Di Castelnuovo, A
    Nasso, G
    Burzotta, F
    Iacoviello, L
    Donati, MB
    Schiavello, R
    Maseri, A
    Possati, G
    CIRCULATION, 2003, 108 (10) : 195 - 199
  • [4] Prognostic value of interleukin-6 in atrial fibrillation: A cohort study and meta-analysis
    Jia, Xiaoyue
    Cheng, Xi
    Wu, Na
    Xiang, Ying
    Wu, Long
    Xu, Bin
    Li, Chengying
    Zhang, Zhihui
    Tong, Shifei
    Zhong, Li
    Li, Yafei
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2021, 25 (12) : 872 - +
  • [5] Is inflammation linked to thrombogenesis in atrial fibrillation?
    Gao, Shu-Ping
    Deng, Xin-Tao
    Ge, Li-Jun
    Luan, Hong
    Zheng, Jin-Guo
    Chen, Chu
    Jiang, Min-Hui
    Pan, Min
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 149 (02) : 260 - 261
  • [6] Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study
    Amdur, Richard L.
    Mukherjee, Monica
    Go, Alan
    Barrows, Ian R.
    Ramezani, Ali
    Shoji, Jun
    Reilly, Muredach P.
    Gnanaraj, Joseph
    Deo, Raj
    Roas, Sylvia
    Keane, Martin
    Master, Steve
    Teal, Valerie
    Soliman, Elsayed Z.
    Yang, Peter
    Feldman, Harold
    Kusek, John W.
    Tracy, Cynthia M.
    Raj, Dominic S.
    PLOS ONE, 2016, 11 (02):
  • [7] Increased serum interleukin-6 level as a predictive biomarker for atrial fibrillation: A systematic review and meta-analysis
    Zhou, Peng
    Waresi, Maieryemu
    Zhao, Yikai
    Lin, Hung-Chen
    Wu, Bangwei
    Xiong, Nanqing
    Li, Huiyang
    Huang, Qingyu
    Luo, Xinping
    Li, Jian
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2020, 39 (12) : 723 - 728
  • [8] Atrial Fibrillation in Patients With Chronic Obstructive Pulmonary Disease Is Associated With Polymorphism of Interleukin 6 Gene
    Volchkova, E. A.
    Nikitin, A. G.
    Zotova, I. V.
    Zateyshchikova, A. A.
    Shavrin, I. V.
    Safaryan, V. I.
    Nosikov, V. V.
    Zateyshchikov, D. A.
    KARDIOLOGIYA, 2015, 55 (11) : 31 - 36
  • [9] INCREASED MARKERS OF THROMBOGENESIS IN CHRONIC ATRIAL-FIBRILLATION - EFFECTS OF WARFARIN TREATMENT
    LIP, GYH
    LOWE, GDO
    RUMLEY, A
    DUNN, FG
    BRITISH HEART JOURNAL, 1995, 73 (06): : 527 - 533
  • [10] Preventing atrial fibrillation in COVID-19: exploring the role of interleukin-6 receptor antagonists
    Kow, Chia Siang
    Ramachandram, Dinesh Sangarran
    Hasan, Syed Shahzad
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2023, 21 (10) : 713 - 714